Year
2023
Authors
PUYOU DE POUVOURVILLE Gérard, GUERCI Bruno, ROUSSEL Ronan, LEVRAT-GUILLEN Fleur, DETOURNAY Bruno, VICAUT Eric, EMERY Corinne, RIVELINE Jean-Pierre
Abstract
Introduction/Aims Initiation of insulin therapy in people withT2DM may be necessary to achieve glycemic targets but is associated with acute diabetes events (ADEs), including severe hypoglycemia (SH) or diabetic ketoacidosis (DKA). We assessed the impact of initiating FreeStyle Libre® glucose monitoring system (FSL) on hospitalizations for ADEs in people with T2DM on basal insulin only regimen +/- non-insulin antidiabetic drugs Methods A retrospective study of the French national SNDS reimbursement claims database (≈66 million French people) identified people with T2DM on basal insulin therapy receiving a first reimbursement of FSL between 01/08/2017 to 31/12/2018. Claims data for the 12 months before, and up to 24 months after FSL initiation, were analyzed. Hospitalizations for ADEs were identified, using ICD-10 codes as main or related diagnosis, for: SH events; DKA events; comas; and hyperglycemia-related admissions. Results 5,933 people with T2DM on basal insulin therapy initiated FSL during the selection period. 78.9% of patients were on basal insulin and other hypoglycemic agents. Amongst the 5,933 patients identified, 2.01% had at least one hospitalization for any ADE in the year before FSL initiation, compared to 0.75% (1 year) and 0.60% (2 years). Reductions in ADEs were driven by 75% fewer DKA admissions, with a 44% reduction in SH admissions. These patterns of reduced ADEs persisted after 2 years, with a further 43% reduction in DKA rates. Conclusions This study emphasizes the value of the FSL system in reducing ADEs in people with T2DM in France not on intensive insulin therapy and initially treated with basal-only insulin therapy.
GUERCI, B., ROUSSEL, R., LEVRAT-GUILLEN, F., DETOURNAY, B., VICAUT, E., PUYOU DE POUVOURVILLE, G. … RIVELINE, J.P. (2023). Important decrease in hospitalizations for acute diabetes events following FreeStyle Libre® system initiation in people with type 2 diabetes on basal insulin therapy in France. Diabetes Technology & Therapeutics, 25(1), pp. 1-30.